Hims & Hers unlocks full access to FDA-approved GLP-1 weight-loss drugs
Hims & Hers rose in early trading after it announced that it now allows its providers to prescribe medications that are fulfilled by independent pharmacies, meaning its members can access all FDA-approved GLP-1s.
Hims providers can now send prescriptions for Eli Lilly's popular weight-loss medications to the drugmaker's direct-to-consumer pharmacy, Lilly Direct. Previously they were able to send prescriptions only to partner pharmacies.
Hims has historically pushed copycat versions of injectable GLP-1s. It launched a copy of Novo Nordisk's Wegovy pill earlier this year, which was ultimately pulled after massive blowback. Hims now partners with Novo to distribute its branded GLP-1s. (Today's development is not a partnership with Lilly.)
In announcing the move, Hims CEO Andrew Dudum compared his company's business model to Netflix.
"By offering a full range of FDA-approved GLP-1s on our platform, we're similarly giving our customers more choices through all the tools we have available - and we'll continue to push here on behalf of everyone who depends on us for their care," Dudum said in an X post.
